Search
for
Sort by
Research 31–60 of 1000+
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Aldesleukin
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Reporting on Adverse Clinical Events
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care
- Efficacy and safety of α-blockers plus 5α-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis
- Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- A Phase 1 Study to Investigate the Effects of Cortexolone 17α‐Propionate, Also Known as Clascoterone, on the QT Interval Using the Meal Effect to Demonstrate ECG Assay Sensitivity
- Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Health consequences of anabolic steroids: a sexual-medicine perspective
- What does the research say about androgen use and cerebrovascular events?
- Adverse health effects of androgen use
- Adverse Reactions to Oral Retinoids An Update
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
- Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence
- Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Cellular therapeutics and immunotherapies in wound healing – on the pulse of time?